Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer.
about
Recent advances in the management of renal cell carcinomaT-cell exhaustion in allograft rejection and toleranceRecent advances in therapeutic cancer vaccinesImmunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulationTargeting the PD-1 pathway: a promising future for the treatment of melanoma.Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established blood-stage Plasmodium infectionThe PDL1-PD1 axis converts human TH1 cells into regulatory T cells.Positive and negative regulation of cellular immune responses in physiologic conditions and diseasesTherapeutic cancer vaccines: current status and moving forward.Trial Watch: Monoclonal antibodies in cancer therapyVirotherapy, gene transfer and immunostimulatory monoclonal antibodies.Programmed death 1 protects from fatal circulatory failure during systemic virus infection of mice.Strategies and developments of immunotherapies in osteosarcomaLocally advanced lung cancer: an optimal setting for vaccines and other immunotherapies.Programmed death-1 is a marker for abnormal distribution of naive/memory T cell subsets in HIV-1 infection.Interleukin-7 and immune reconstitution in cancer patients: a new paradigm for dramatically increasing overall survivalIntratumoral heterogeneity as a therapy resistance mechanism: role of melanoma subpopulations.Engineering better immunotherapies via RNA interferenceProgrammed death-1 gene polymorphism (PD-1.5 C/T) is associated with gastric cancer.The ultimate goal of curative anti-cancer therapies: inducing an adaptive anti-tumor immune response.The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment.In vitro and in vivo cytotoxic effect of AntiGan against tumor cells.Intratumor heterogeneity of immune checkpoints in primary renal cell cancer: Focus on HLA-G/ILT2/ILT4.Trial watch: Monoclonal antibodies in cancer therapy
P2860
Q26750609-333F3B2D-7641-472F-9295-74C624E008D9Q26865338-3956A16A-5846-42E4-BC0E-41789F778309Q27025266-9058CFC4-23BA-4FCA-97B4-8C91AD85C24FQ33848077-8A52090E-3121-4DC1-B173-BFC3CE8A0314Q33946513-31C44E5C-6780-47B0-9F23-17F3B2E4CD8CQ34239730-76F21941-07E2-447A-AC6F-2CB1C5B2DC06Q35607698-1E8CDBD5-4814-4B11-8A8B-F8B0138EF9C9Q35883043-395443C3-26E4-4B6A-B2D6-DDDB1C98D2C8Q35894347-5D34E637-3A3A-4A4D-A8FF-254F38C2A271Q36038408-781F8EC3-BF3E-4E5B-B599-8E6E41FF4A82Q36456487-2812E2D4-D9FA-4313-8535-D07FA87F9D3FQ36478253-8A81C684-0750-4742-B96F-CCCB75210731Q36503128-E93A7AA8-86C8-4401-BBDC-34BF8D4F0A2EQ36946100-A370CC15-2A93-4A92-9835-465797AF355AQ37273690-6DB067AE-F128-4F36-B882-7C24B85B2A92Q37989867-B7D1B6EA-BBE8-40FF-8676-250688A2C046Q38041729-57446302-DAD0-403E-ABFC-DE46937EC89CQ38284703-82D0F8B1-5657-4843-A994-9565BFDE550CQ39492374-05011611-CD2D-4655-BB6B-1DBCC0605493Q42143991-0F3133C5-DD15-4AEF-A82F-CEDEE34174B7Q43215888-F1198AB6-CA16-4D9C-9FEA-3FEB92658546Q50287987-A3000213-A9E5-43DF-B0C2-BBC1BCA3B829Q53064214-D59A42DF-FA4D-44AE-AB09-6C3BCC683E37Q56932681-FFB08C28-54A8-4A2F-89C7-02168315CCD9
P2860
Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer.
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer.
@ast
Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer.
@en
Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer.
@nl
type
label
Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer.
@ast
Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer.
@en
Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer.
@nl
prefLabel
Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer.
@ast
Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer.
@en
Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer.
@nl
P1476
Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer
@en
P2093
Justin Kline
Thomas F Gajewski
P304
P577
2010-12-01T00:00:00Z